ArticleCureus2025
Predictors of Response to Treatment With Anti-calcitonin Gene-Related Peptide (CGRP) Antibodies in Real-World Patients With Episodic Migraine: A Two- and Four-Month Prospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonoclonal antibodies (mAbs) for anti-calcitonin gene-related peptide (CGRP) have emerged as an effective and well-tolerated option for alleviating migraine burden and improving patients' quality of life. There is limited understanding of the specific clinical and biological predictors that forecast sustained response to anti-CGRP antibodies in real-world episodic migraine patients. This study was designed to estimate the proportion and potential predictors of response (≥50% response rate) at two months and four months in real-world patients with episodic migraine who received this therapy as their only preventive treatment.
methodThis is an open prospective study carried out in consecutive episodic migraine patients (International Classification of Headache Disorders (ICHD)-3) with six to 10 monthly headache days (MHD), seen for the first time from January 2023 to May 2024 in a tertiary center, to whom a monoclonal antibody anti-CGRP (fremanezumab or galcanezumab) was prescribed as the only preventive treatment. Sixty-three patients fulfilled the eligibility criteria. The patients were evaluated in long-lasting initial consultations, and follow-up visits were carried out after two and four months. Data was collected using a semi-structured proforma and a detailed headache diary.
resultsThere was a significant reduction in the migraine frequency as measured by MHD from baseline to two months and four months after intervention (P=0.000, 8.85±1.17 days at baseline to 6.39±3.60 at two months and 6.35±3.25 at four months). The reduction in MHD was significantly higher among those who had a normal BMI as compared to the participants who were overweight (P=0.000) and those who had unilateral headaches (P=0.013) and severe osmophobia during attacks (P=0.035). Approximately 39.7% (n=25) of participants achieved a ≥50% reduction in MHD at both two and four months.
conclusionNormal BMI was found to be significantly associated with a reduction in migraine frequency of >50%, whereas normal BMI, unilateral headache, and severe osmophobia were significantly associated with a mean MHD reduction. Further controlled studies with several other factors predicting response to anti-CGRP mAbs are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.